HEALTH CARE UTILIZATION AND COSTS AFTER WARFARIN DISCONTINUATION AMONG PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
Author(s)
Wang J1, Qiao Y1, Spivey CA1, Liu X2, Phatak H3, Mardekian J4, Claflin AB4, Kachroo S3, Abdulsatter Y4, Parker RB1
1The University of Tennessee College of Pharmacy, Memphis, TN, USA, 2University of Tennessee, College of Pharmacy, New York, NY, USA, 3Bristol-Myers Squibb Company, Princeton, NJ, USA, 4Pfizer, Inc., New York, NY, USA
METHODS: A retrospective observational study was conducted among patients (≥18 years of age) with non-valvular AF who were on warfarin in the US MarketScan Database (01/2008-06/2012). Warfarin discontinuation was identified by a gap >45 days in warfarin prescriptions within one year of warfarin initiation. A propensity score method was used to match WP patients and WD patients to produce compatible index dates. Patients’ follow-up started from the discontinuation date for WD patients and after the same duration of warfarin therapy for matched WP patients. Patients were followed for up to one year to determine the annualized number and costs of health care utilization. To adjust for patient characteristics, multivariate analyses were conducted.
RESULTS: 27,000 matched patients were included for the analysis. Mean follow-up duration was 264 days for WD and 339 days for WP groups. Compared with WP patients, WD patients were more likely to be hospitalized (Mean: 0.51 vs. 0.37, P<0.001) and to visit ER (Mean: 1.14 vs. 1.01, P<0.001). The total annualized costs in WD group was significantly higher than WP group ($24,701.2 vs. $19,836.3, P<0.001). Hospitalization accounted for 34.57% of total costs. After adjusting for patient characteristics, the patterns of differences between the two groups remain the same. CONCLUSIONS: Warfarin discontinuation is associated with higher number of hospitalizations and ER visits and higher total health care costs than warfarin persistence. Future studies should examine strategies to improve patient persistence with anticoagulants and lower total health care costs.
Conference/Value in Health Info
Value in Health, Vol. 17, No. 7 (November 2014)
Code
PCV4
Topic
Clinical Outcomes, Epidemiology & Public Health
Topic Subcategory
Comparative Effectiveness or Efficacy, Safety & Pharmacoepidemiology
Disease
Cardiovascular Disorders